Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson continues to grow, albeit at a very modest GDP + pace. The company closed the Abiomed deal already, while maintaining balance sheet integrity.

Johnson & Johnson: Starting To Look Interesting Again

The company's court loss over baby-powder litigation could force it to defend thousands of lawsuits case by case, just as it navigates the biggest restructuring in its 137-year history.

J&J Faces Longer Path to Resolving Talc Lawsuits

A federal appeals court rejects J&J's (JNJ) efforts to shift over 38,000 lawsuits related to its talcum-based baby powder out of trial courts and into bankruptcy court.

J&J (JNJ) Down as Court Rejects Bankruptcy Claim in Talc Lawsuits

AbbVie

Coca-Cola

PepsiCo

Procter & Gamble

According to the All-in-one Screener, a Premium feature of GuruFocus, five dividend kings stocks that have high guru ownership as of the third-quarter 2022 13F portfolio filings are Johnson & Johnson ( JNJ , Financial), Proctor & Gamble Co. ( PG , Financial), Coca-Cola Co. ( KO , Financial), AbbVie Inc. ( ABBV , Financial) and PepsiCo Inc. ( PEP , Financial).

5 Dividend King Stocks Gurus Are Feasting On

Nachawati Law Group: Ovarian cancer victims deserve day in court PHILADELPHIA , Jan. 30, 2023 /PRNewswire/ -- Trial lawyers with the Nachawati Law Group praised a ruling by the U.S. Court of Appeals for the Third Circuit rejecting Johnson & Johnson's (NYSE: JNJ) use of a controversial bankruptcy ploy to shed more than 38,000 lawsuits filed by women who developed ovarian cancer after using J&J's talc-based products. The Jan. 30 ruling means J&J can be held accountable for its failure to warn consumers about known cancer risks associated with talc-based products like Johnson's Baby Powder, said trial lawyer Majed Nachawati , founder of Dallas-based Nachawati Law Group.

Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits

Johnson & Johnson (NYSE:JNJ)'s (J&J) bankruptcy petition has reportedly been dismissed by a US appeals court, dealing a blow to the healthcare giant's efforts to settle billions of dollars in legal claims over allegations that its talcum powder causes cancer. According to the Financial Times and Reuters J&J's subsidiary, LTL management had sought to file for bankruptcy in an effort to transfer thousands of legal claims from trial courts to the bankruptcy system.

Johnson & Johnson's reported bankruptcy tactic blocked by US appeal court

The fallout from the baby powder controversy continues to damage the company.

Why Johnson & Johnson Stock Slipped by Nearly 4% on Monday

Chevron

Investors dealt with a pause in the January rally.

These 2 Stocks Led the Dow Lower Monday

An appeals court on Monday dismissed the Chapter 11 bankruptcy petition of J&J's talc subsidiary, which the company formed to resolve thousands of lawsuits.

Court tosses bankruptcy petition by Johnson & Johnson's talc unit

Johnson and Johnson's stock took a tumble before its Q4 2022 earnings call, and the numbers reported didn't help it bounce back. Here's what happened.

Johnson And Johnson Stock Slips After Missing The Mark For Earnings

Johnson & Johnson continues to stand by the safety of its baby powder formula and has denied that it contains cancer-causing asbestos.

Johnson and Johnson loses $17 billion in market value after appeals court denies company bankruptcy escape in baby powder lawsuits

It's a sea of red in the stock market today, but some companies are clearly under-performing others. One such notable decliner today is Johnson & Johnson (NYSE: JNJ ), with shares of JNJ stock dropping 4% in early afternoon trading.

Why Is Johnson & Johnson (JNJ) Stock Down Today?

A federal court said J&J can't rely on a bankruptcy filing to resolve litigation related to its baby powder. JNJ stock tumbled Monday.

J&J Dives After Court Denies Bankruptcy For Litigation-Hamstrung Baby Powder Division

A federal appeals court said Johnson & Johnson's LTL Management can't use bankruptcy to resolve numerous talc-injury lawsuits.

J&J's Talc Bankruptcy Case Thrown Out by Appeals Court

Johnson & Johnson's strategy to use bankruptcy to resolve the multibillion-dollar litigation over claims its talc products cause cancer was rejected by a federal appeals court on Monday, but the healthcare conglomerate said it would challenge the ruling.

Johnson & Johnson's talc bankruptcy case rejected by appeals court

Shares of Johnson & Johnson JNJ, -2.56% took a dive in midday trading Monday, after The Wall Street Journal reported that a federal appeals court rejected the consumer products and drug maker's move to place its talc liabilities into bankruptcy. The stock was down 2.8%, enough to pace the Dow Jones Industrial Average's decliners.

Johnson & Johnson stock takes a dive after WSJ report that federal appeals court rejected talc bankruptcy case

Emerson Electric

Stanley Black & Decker

These Dividend Kings have increased dividends consecutively for 55 years or more and look hugely compelling right now.

3 Dividend Kings to Buy Hand Over Fist in 2023

Plus, Motley Fool personal finance expert Robert Brokamp answers your questions.

2 Blue Chips Under Pressure

CVS Health

UnitedHealth Group

These solid stocks are down but definitely not out.

3 Beaten-Down Blue Chip Stocks to Buy Right Now

Abbott Labs

Automatic Data Processing

Aflac

Cigna

Colgate-Palmolive

Clorox

Cisco Systems

Intel

Illinois Tool Works

Lockheed Martin

Medtronic

Microsoft

QUALCOMM

Rio Tinto plc Sponsored

AT&T

Walgreens

Waste Management

Walmart

We present the 2022 year-end review of our eight-year-old Passive DGI-Core Portfolio. We consider this portfolio and strategy as the foundation of our overall portfolio. We will provide updates on changes, additional investments, dividends collected, and an overall 2022 performance.

The 4% DGI Core Portfolio: 2022 Year-End Review

Easterly Government Properties

These stocks should allow you to sleep peacefully no matter what happens with the stock market this year.

3 Low-Risk Dividend Stocks to Buy in 2023

You can count on them for passive income and growth over time.

2 of the Best Dividend Stocks to Own in 2023

Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today's market. They offer relatively high yields and at least some value while projecting growth in 2023.

News for Johnson & Johnson Stock (JNJ)